Literature DB >> 15770418

Proteinaceous cysteine protease inhibitors.

G Dubin1.   

Abstract

Studies of proteinaceous cysteine protease inhibitors originated with the discovery of cystatins in the 1960s. Since that time, a rich and fascinating world of proteins that control and regulate a multitude of important physiological processes, ranging from the basics of protein turnover to development and brain function, has been uncovered. Failures in such important and complex systems inevitably lead to pathologies. Many threatening diseases such as cancer or neurological disorders, to mention only some, are attributed to deregulation of protease-inhibitor balance. Moreover, important aspects of infection pathology and host defense rely on proteolysis and protease inhibition. Recent advances in the field of protease inhibitors have drawn attention to the possible use of this collected knowledge to control related pathological processes. This review attempts to familiarize the reader with proteinaceous cysteine protease inhibitors by providing an overview of current knowledge. The work primarily highlights biological processes in which the inhibitors are involved and focuses on pathologies resulting from aberrant protease-inhibitor balance, pointing out emerging possibilities for their correction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770418      PMCID: PMC7079805          DOI: 10.1007/s00018-004-4445-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  39 in total

Review 1.  Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths.

Authors:  Allan D Struthers; Andrew D Morris
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

2.  Circulating endothelial cells in patients with septic shock.

Authors:  M Mutunga; B Fulton; R Bullock; A Batchelor; A Gascoigne; J I Gillespie; S V Baudouin
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

3.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.

Authors:  P H Stone; J E Muller; T Hartwell; B J York; J D Rutherford; C B Parker; Z G Turi; H W Strauss; J T Willerson; T Robertson
Journal:  J Am Coll Cardiol       Date:  1989-07       Impact factor: 24.094

4.  Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.

Authors:  Yi-Chang Cheng; Li-Mien Chen; Mu-Hsin Chang; Wei-Kung Chen; Fuu-Jen Tsai; Chang-Hai Tsai; Tung-Yuan Lai; Wei-Wen Kuo; Chih-Yang Huang; Chung-Jung Liu
Journal:  Mol Cell Biochem       Date:  2009-01-28       Impact factor: 3.396

5.  Rac1 is required for cardiomyocyte apoptosis during hyperglycemia.

Authors:  E Shen; Yanwen Li; Ying Li; Limei Shan; Huaqing Zhu; Qingping Feng; J Malcolm O Arnold; Tianqing Peng
Journal:  Diabetes       Date:  2009-07-10       Impact factor: 9.461

Review 6.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

7.  Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy.

Authors:  Nobutake Shimojo; Subrina Jesmin; Sohel Zaedi; Takeshi Otsuki; Seiji Maeda; Naoto Yamaguchi; Kazutaka Aonuma; Yuichi Hattori; Takashi Miyauchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-16       Impact factor: 4.733

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

Review 9.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

10.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people.

Authors:  Anoop Dinesh Shah; Claudia Langenberg; Eleni Rapsomaniki; Spiros Denaxas; Mar Pujades-Rodriguez; Chris P Gale; John Deanfield; Liam Smeeth; Adam Timmis; Harry Hemingway
Journal:  Lancet Diabetes Endocrinol       Date:  2014-11-11       Impact factor: 32.069

View more
  26 in total

1.  The Spn4 gene from Drosophila melanogaster is a multipurpose defence tool directed against proteases from three different peptidase families.

Authors:  Mareke Brüning; Martina Lummer; Caterina Bentele; Marcel M W Smolenaars; Kees W Rodenburg; Hermann Ragg
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

2.  Proteomic analysis of adult S. mansoni gut contents.

Authors:  Melaine Delcroix; Katalin Medzihradsky; Conor R Caffrey; Richard D Fetter; James H McKerrow
Journal:  Mol Biochem Parasitol       Date:  2007-03-20       Impact factor: 1.759

3.  Crystallization and preliminary X-ray crystallographic analysis of the cysteine protease inhibitor clitocypin.

Authors:  Katja Galesa; Joze Brzin; Jerica Sabotic; Dusan Turk
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-12-16

4.  Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.

Authors:  Yisel Cantres-Rosario; Marines Plaud-Valentín; Yamil Gerena; Richard L Skolasky; Valerie Wojna; Loyda M Meléndez
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

Review 5.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

Review 6.  Microbial inhibitors of cysteine proteases.

Authors:  Mateusz Kędzior; Rafał Seredyński; Jan Gutowicz
Journal:  Med Microbiol Immunol       Date:  2016-04-05       Impact factor: 3.402

7.  The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation.

Authors:  Daniel J Morgan; Suwen Wei; Ivone Gomes; Traci Czyzyk; Nino Mzhavia; Hui Pan; Lakshmi A Devi; Lloyd D Fricker; John E Pintar
Journal:  J Neurochem       Date:  2010-03-26       Impact factor: 5.372

Review 8.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Authors:  Yanwen Qin; Guo-Ping Shi
Journal:  Pharmacol Ther       Date:  2011-05-12       Impact factor: 12.310

9.  Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome.

Authors:  Stefan Tholen; Martin L Biniossek; Martina Gansz; Alejandro Gomez-Auli; Fee Bengsch; Agnes Noel; Jayachandran N Kizhakkedathu; Melanie Boerries; Hauke Busch; Thomas Reinheckel; Oliver Schilling
Journal:  Mol Cell Proteomics       Date:  2012-12-10       Impact factor: 5.911

10.  Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

Authors:  Sara Sjöberg; Guo-Ping Shi
Journal:  Clin Rev Bone Miner Metab       Date:  2011-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.